Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult issue in cancer immunotherapy: the way immunotherapy-related approaches focused on short-term killing of tumor cells may fail to eradicate tumors because growth of tumors happens on longer timescales.
Immunotherapy has the potential to eliminate tumors, but works best for select patients. Engineering T cells to bypass cancer’s defenses could help expand treatment eligibility to more patients.
At number 18 on IE's 22 best innovations of 2022, we take a look back at the 'biohybrid microrobots' that could one day tackle cancer tumors.
A new review was published in Oncotarget's Volume 13 on November 17, 2022, entitled, "Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more."
Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.